期刊
CANCERS
卷 14, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/cancers14010022
关键词
venetoclax; acute myeloid leukemia; relapsed; refractory; off-label; regulatory issue
类别
资金
- regional pharmacovigilance project AIFA 2010/2011 project [304 ADR-648]
- PON AIM RI 2014-2020 [E66C18001260007]
This review summarizes the evidence on the use of Venetoclax (VEN) regimens in the treatment of relapsed/refractory acute myeloid leukemia (AML) patients. Despite the development of new therapeutic strategies, there is still a high medical need for improved treatments in this patient population.
Simple Summary Venetoclax (VEN) is a potent oral inhibitor of the anti-apoptotic molecule BCL2, approved for adults with chronic lymphocytic leukemia (CLL), and recently for naive acute myeloid leukemia (AML) unfit for intensive chemotherapy. Therefore, VEN is not approved for relapsed/refractory (R/R) AML patients; consequently, this use falls within the so-called off-label use. This review provides evidence of the role of VEN-based therapy in R/R AML patients, including data from clinical trials and from retrospective studies. Despite the progress in the development of new therapeutic strategies, relapsed/refractory (R/R) acute myeloid leukemia (AML) still represents a high unmet medical need. Treatment options in this setting include enrollment into clinical trials, allogeneic stem cell transplantation and/or targeted therapy. Nevertheless, it is associated with poor outcomes. Thus, the development of new treatments, which could ameliorate the prognosis of these patients with a good safety profile are highly demanded. Recently, venetoclax (VEN) has been approved for naive AML patients unfit for intensive chemotherapy. In this regard, regimens including VEN could represent a valuable treatment option even in those with R/R disease and several studies have been conducted to demonstrate its role in this clinical setting. This review aims to summarize the current evidence on the use of VEN regimens in the treatment of R/R AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据